Skip to main content
OpenTrials

Clinical trial condition

Relapsing Remitting Multiple Sclerosis

Explore clinical trials studying Relapsing Remitting Multiple Sclerosis. Study availability and eligibility vary by location and protocol.

84 public trials 6 recruiting studies
Refine in advanced search Browse all conditions

Relapsing Remitting Multiple Sclerosis trial results

Completed

Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.

NCT01623596

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Novartis Investigative Site Cullman, Alabama, United States
  • Novartis Investigative Site Phoenix, Arizona, United States
  • Novartis Investigative Site Sun City, Arizona, United States
  • Novartis Investigative Site Tucson, Arizona, United States
View all 123 locations
View Trial Details
Completed

Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy

NCT03177083

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Hospital Fernando Fonseca Amadora, Portugal
  • Hospital de Braga Braga, Portugal
  • Centro Hospitalar Cova da Beira Covilha, Portugal
  • Hospital Evora Evora, Portugal
View all 15 locations
View Trial Details
Completed

Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis

NCT02424396

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Centre d'investigation Clinique - Pitié salpêtrière Paris, France
  • Centre d'investigation clinique Biothérapie Immunologie (CIC-BTi) - Groupe Hospitalier Pitié-Salpêtrière - AP-HP Paris, France
  • Département des maladies du système nerveux et Centre d'investigation clinique - Groupe Hospitalier Pitié-Salpêtrière - AP-HP Paris, France
View Trial Details
Completed

A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2

NCT03093324

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Alkermes Investigational Site Cullman, Alabama, United States
  • Alkermes Investigational Site Phoenix, Arizona, United States
  • Alkermes Investigational Site Tucson, Arizona, United States
  • Alkermes Investigational Site Long Beach, California, United States
View all 67 locations
View Trial Details
Completed

Fingolimod Effect on Cytokine and Chemokine Levels

NCT02373098

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Novartis Investigative Site Mecidiyeköy, Istanbul, Turkey (Türkiye)
  • Novartis Investigative Site Üsküdar, Istanbul, Turkey (Türkiye)
  • Novartis Investigative Site Istanbul, Turkey (Türkiye)
View Trial Details
Completed

PROFILE - Evaluation of QoL and PRO Outcomes in Patients Taking Fingolimod

NCT02335892

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Novartis Investigative Site Truro, Cornwall, United Kingdom
  • Novartis Investigative Site Swansea, England, United Kingdom
  • Novartis Investigative Site Romford, Essex, United Kingdom
  • Novartis Investigative Site Basingstoke, Hampshire, United Kingdom
View all 14 locations
View Trial Details

Related conditions